This company listing is no longer active
MOR Stock Overview
Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MorphoSys AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €67.75 |
| 52 Week High | €67.95 |
| 52 Week Low | €65.20 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0.82% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| MOR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | -0.3% |
| 1Y | n/a | -14.3% | 7.0% |
Return vs Industry: Insufficient data to determine how MOR performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how MOR performed against the German Market.
Price Volatility
| MOR volatility | |
|---|---|
| MOR Average Weekly Movement | 0.3% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MOR has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine MOR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 464 | Arkadius Pichota | www.morphosys.com |
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.
MorphoSys AG Fundamentals Summary
| MOR fundamental statistics | |
|---|---|
| Market cap | €2.55b |
| Earnings (TTM) | -€494.62m |
| Revenue (TTM) | €249.55m |
10.2x
P/S Ratio-5.2x
P/E RatioIs MOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOR income statement (TTM) | |
|---|---|
| Revenue | €249.55m |
| Cost of Revenue | €59.71m |
| Gross Profit | €189.84m |
| Other Expenses | €684.46m |
| Earnings | -€494.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.13 |
| Gross Margin | 76.07% |
| Net Profit Margin | -198.20% |
| Debt/Equity Ratio | -518.3% |
How did MOR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/21 21:50 |
| End of Day Share Price | 2024/10/15 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MorphoSys AG is covered by 35 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olav Zilian | Baader Helvea Equity Research |
| Brian Balchin | Barclays |
| Rosie Turner | Barclays |